Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in Moderate to Severe Atopic Dermatitis
NCT07103174Phase 2Completed
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of comekibart in atopic dermatitis (AD), sponsored by Hunan Mabgeek Biotechnology. Started Jun 2025; status: completed.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07103174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103174.